TRAVASOL 600 MG / 100 ML — DIN 00872296
ISOLEUCINE : 600 MG / 100 ML GLYCINE : 1.03 G / 100 ML L-ALANINE : 2.07 G / 100 ML TYROSINE : 40 MG / 100 ML HISTIDINE : 480 MG / 100 ML SERINE : 500 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML METHIONINE : 400 MG / 100 ML ARGININE : 1.15 G / 100 ML LEUCINE : 730 MG / 100 ML THREONINE : 420 MG / 100 ML PROLINE : 680 MG / 100 ML PHENYLALANINE : 560 MG / 100 ML VALINE : 580 MG / 100 ML · BAXTER CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is TRAVASOL?
TRAVASOL 600 MG / 100 ML contains ISOLEUCINE : 600 MG / 100 ML GLYCINE : 1.03 G / 100 ML L-ALANINE : 2.07 G / 100 ML TYROSINE : 40 MG / 100 ML HISTIDINE : 480 MG / 100 ML SERINE : 500 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML METHIONINE : 400 MG / 100 ML ARGININE : 1.15 G / 100 ML LEUCINE : 730 MG / 100 ML THREONINE : 420 MG / 100 ML PROLINE : 680 MG / 100 ML PHENYLALANINE : 560 MG / 100 ML VALINE : 580 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00872296, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Oct-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRAVASOL used for?
Source of amino acids in parenteral nutrition when enteral supply is insufficient or impossible, to prevent nitrogen loss or negative nitrogen balance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Amino Acids in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Amino Acids, across 26 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 8 | 3 | 20% PROSOL, BCAA 4% INJ, PRIMENE 10%, RENAMIN (AMINO ACIDS) INJECTION, TRAVASOL, +2 more | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | ESSEPNA | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 8 | 0 | AMINOSYN 5%, AMINOSYN 7%, AMINOSYN 8.5%, AMINOSYN II 7% INJECTION, AMINOSYN II 8.5% INJECTION, +3 more | No marketed DIN |
| ICU MEDICAL CANADA INC | 3 | 0 | AMINOSYN, AMINOSYN II | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 2 | 0 | AMINOSYN II 5% INJ, L CYSTEINE HCL INJ 50MG/ML | No marketed DIN |
| B. BRAUN MEDICAL INC | 2 | 0 | 8.5% FREAMINE III, NEPHRAMINE LIQ IV | No marketed DIN |
| BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 1 | 0 | 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX | No marketed DIN |
| FRESENIUS KABI AB | 1 | 0 | VAMIN 18 ELECTROLYTE-FREE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 600 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Available in 1000 mL bags (Viaflex plastic container). |
| Storage | Store at 15-30°C. Protect from light. Do not freeze. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Amino Acids |
|---|---|
| ATC code | B05BA01 |
| AHFS class | 40:20.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00872296 |
|---|---|
| DIN (unpadded, as printed on some documents) | 872296 |
| Brand name | TRAVASOL |
| Generic / active ingredient | ISOLEUCINE : 600 MG / 100 ML GLYCINE : 1.03 G / 100 ML L-ALANINE : 2.07 G / 100 ML TYROSINE : 40 MG / 100 ML HISTIDINE : 480 MG / 100 ML SERINE : 500 MG / 100 ML L-LYSINE (L-LYSINE HYDROCHLORIDE) : 580 MG / 100 ML TRYPTOPHAN : 180 MG / 100 ML METHIONINE : 400 MG / 100 ML ARGININE : 1.15 G / 100 ML LEUCINE : 730 MG / 100 ML THREONINE : 420 MG / 100 ML PROLINE : 680 MG / 100 ML PHENYLALANINE : 560 MG / 100 ML VALINE : 580 MG / 100 ML |
| Market authorization holder | BAXTER CORPORATION |
| Health Canada schedule | Ethical |
| ATC code | B05BA01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05BA |
| Current status | MARKETED |
| Status date | 16-Oct-2013 |
| Original market date | 1991-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Pharmacy bulk package. Dosage based on metabolic requirements. Adults: 1.0 to 1.5 g/kg/day. Infants: 2 to 3 g/kg/day. Administer via central vein for hypertonic mixtures.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; severe liver failure or hepatic coma; congenital amino acid metabolism abnormality. TRAVASOL E: acute renal failure (without RRT), hyperkalemia, hypercalcaemia, hypernatremia.
Warnings and precautions
Risk of pulmonary vascular precipitates. Monitor for infection/sepsis. Avoid air embolism. Monitor for hyperammonemia and refeeding syndrome. Protect from light for neonates/children <2 years.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 26 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 20% PROSOL | 1.18 G / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | 02141450 |
| ESSEPNA | 1.1 G / 100 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02510324 |
| PRIMENE 10% | 189 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | 02236875 |
| 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX | 76 MG / 100 ML | SOLUTION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | 02013908 |
| 8.5% FREAMINE III | 770 MG / 100 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | 02158647 |
| AMINOSYN | 440 MG / 100 ML | SOLUTION | ICU MEDICAL CANADA INC | CANCELLED POST MARKET | 00454907 |
| AMINOSYN 5% | 220 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00404160 |
| AMINOSYN 7% | 690 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00523232 |
| AMINOSYN 8.5% | 624 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00613320 |
| AMINOSYN II | 172 MG / 100 ML | SOLUTION | ICU MEDICAL CANADA INC | DORMANT | 00742619 |
2 · Same class — other molecules in ATC B05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Combinations | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE · 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX · 2.5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 10% DEXTROSE QUICKMIX · 2.5%TRAVASOL AMINO ACID INJ.W.ELEC.W.25%DEX · +51 more | 79 | 22 | Yes |
| Carbohydrates | 10% DEXTROSE INJECTION USP · 10% DEXTROSE INJECTION, USP · 13.3% DEXTROSE INJECTION, USP · 20% DEXTROSE INJECTION USP · +18 more | 32 | 9 | Yes |
| Amino Acids | 20% PROSOL · 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX · 8.5% FREAMINE III · AMINOSYN · +20 more | 26 | 4 | Yes |
| Fat Emulsions | 10% TRAVAMULSION LIQ IV · 20% TRAVAMULSION LIQ IV · CLINOLEIC 20% · COLIP 20% · +9 more | 13 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05BB | Electrolytes · Electrolytes With Carbohydrates | 90 | 27 |
| B05BC | Carbamide · Carbamide, Combinations · Mannitol | 11 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.